Sun Pharmaceuticals has received an approval from the Subject Expert Committee (SEC) functional under CDSCO Central Drugs Standard Control Organization, to manufacture Dextromethorphan Hydrobromide 30mg and Chlorpheniramine maleate IP 4mg sustained-release Oral suspension.
Although the approval came with the condition that the firm should conduct a Phase-IV clinical trial and, accordingly, the Phase-IV protocol should be submitted within 03 months from the date of approval.
The committee reviewed the proposal and noted that the FDC of Dextromethorphan Hydrobromide 10mg + Chlorphenaramine maleate 2mg per 5ml is already approved by DCGI.
Dextromethophan, an antitussive agent, is primarily used as a cough suppressant to relieve cough caused by mild throat and bronchial inflammation (such as that which often occurs with the flu and common cold), as well as cough caused by inhaled particle irritants.
Chlorpheniramine is an antihistamine used to control allergies, high fever, and the common cold.
Dysautonomia: The Silent Illness Impacting Millions of People Worldwide Dysautonomia is an umbrella term used…
https://youtu.be/mdl3AFFFcuk?si=i2cYzTX7WJ-z6wRp Does Chyawanprash Help in Cough & Cold? Exploring Its Benefits and Efficacy Chyawanprash, a…
Walk In Winter: In winter, the time from 7:00 AM to 9:00 AM is considered…
Does Maida Stick To Your Gut Lining: In this article, we debunk the common myth…
https://youtu.be/4NTKSfNf1TM?si=Y4xkEOKDUvqpIEZt The Disadvantages of Heating Packaged Milk Milk is a staple in many households and…
A recent study has revealed a growing mental health crisis among teenagers globally, with nearly…